This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
by Zacks Equity Research
BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.
Zacks Investment Ideas feature highlights: Pfizer, Philip Morris and Tenet Healthcare
by Zacks Equity Research
Pfizer, Philip Morris and Tenet Healthcare are part of the Zacks Investment Ideas article.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
3 Stocks to Buy Following Robust Quarterly Results
by Derek Lewis
Throughout the Q3 reporting cycle, several companies, including Pfizer, Philip Morris, and Tenet Healthcare, have stolen the spotlight, with each raising guidance.
Here's Why Pfizer (PFE) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pfizer's Q3 Earnings Beat, Paxlovid Drives Sales Guidance Increase
by Zacks Equity Research
PFE beats third-quarter estimates for earnings and sales. It raises 2024 earnings and revenue expectations.
Case-Shiller Index Reports Annual Rise in Home Prices
by Zacks Equity Research
Case-Shiller Index Reports Annual Rise in Home Prices
Pre-Markets Lower as Investors Seek Equilibrium
by Mark Vickery
After the close this afternoon, we'll see earnings results from Alphabet (GOOGL), AMD (AMD), Chipotle (CMG) and Visa (V), to name but a few.
Pfizer (PFE) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pfizer (PFE) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 65.62% and 16.53%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings?
by Zacks Equity Research
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the third quarter.
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings?
by Ekta Bagri
BMY is looking to turnaround its business, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock, and we recommend it to investors.
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and drug companies, PFE, LLY, ABBV, MRK and BMY, that are scheduled to release their third-quarter 2024 results this week.
Q3 Earnings Preview
by Zacks Equity Research
Q3 Earnings Preview
Collegium Pharmaceutical to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
COLL's Q3 performance is likely to have benefited from higher revenues from the sales of its pain-management drugs and the newly acquired neurology drug.
Jobs Figures, Q3 Earnings Heat Up a Week Before Election
by Mark Vickery
We're a week and a day ahead of the General Election, which is what most investors are waiting on in order to get a clearer sense of direction in the markets.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
On CRSP's third-quarter 2024 earnings call, investors will likely focus on the sales numbers of its recently approved gene therapy, Casgevy.
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News
by Kinjel Shah
Roche announces third-quarter and nine-month results. Sanofi holds exclusive talks with CD&R to sell a 50% stake in Opella.
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.
Will New Drugs Help Biogen Surpass Q3 Earnings Estimates?
by Zacks Equity Research
In the third quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.
Precision BioSciences to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
DTIL is expected to provide updates on its in vivo gene editing programs in the third-quarter earnings release, given the absence of a marketed product.
Gear Up for Pfizer (PFE) Q3 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen
by Zacks Equity Research
Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen are included in this Analyst Blog.
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.